Mustang Bio (MBIO) Other Non-Current Assets (2017 - 2024)
Mustang Bio (MBIO) posted quarterly Other Non-Current Assets of $250000.0 for Q4 2024, down 68.75% year-over-year from $800000.0 in Q1 2024, and little changed quarter-over-quarter from $250000.0 in Q3 2024.
Mustang Bio (MBIO) Other Non-Current Assets (2017 - 2024) Analysis & Trends
Mustang Bio (MBIO) has reported Other Non-Current Assets for 8 consecutive years, with $250000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Non-Current Assets fell 68.75% year-over-year to $250000.0; the TTM figure through Dec 2024 stood at $250000.0 (down 68.75% YoY), while the FY2024 annual figure was $250000.0, down 68.75% from the prior year.
- Other Non-Current Assets was little changed at $250000.0 in Q4 2024 per MBIO's latest filing, from $250000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q3 2020 and bottomed at $250000.0 in Q1 2020.
- Historically, Other Non-Current Assets has averaged $709600.0 across 5 years, with a median of $775000.0 in 2023.
- Annual changes were most pronounced in 2020 — Other Non-Current Assets soared 300.0% — and 2024, when it sank 68.75%.
- Mustang Bio's Other Non-Current Assets stood at $1.0 million in 2020, then slumped by 63.8% to $362000.0 in 2021, then soared by 176.24% to $1.0 million in 2022, then slipped by 20.0% to $800000.0 in 2023, then tumbled by 68.75% to $250000.0 in 2024.
- Business Quant data shows MBIO's Other Non-Current Assets at $250000.0 in Q4 2024, $250000.0 in Q3 2024, and $250000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 250,000.00 |
| Sep 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 530,000.00 |
| Dec 31, 2023 | 800,000.00 |
| Sep 30, 2023 | 750,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 362,000.00 |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Sep 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 250,000.00 |
| Mar 31, 2020 | 250,000.00 |